Reamer Courtney, Chi Wei Ning, Gordon Robert, Sarswat Nitasha, Gupta Charu, Gaznabi Safwan, White VanGompel Emily, Szum Izabella, Morton-Jost Melissa, Vaughn Jorma, Larimer Karen, Victorson David, Erwin John, Halasyamani Lakshmi, Solomonides Anthony, Padman Rema, Shah Nirav S
Department of Medicine, NorthShore University HealthSystem, Evanston, IL, United States.
Outcomes Research Network, NorthShore University HealthSystem, Evanston, IL, United States.
JMIR Res Protoc. 2022 Aug 25;11(8):e36741. doi: 10.2196/36741.
Heart failure (HF) is a prevalent chronic disease and is associated with increases in mortality and morbidity. HF is a leading cause of hospitalizations and readmissions in the United States. A potentially promising area for preventing HF readmissions is continuous remote patient monitoring (CRPM).
The primary aim of this study is to determine the feasibility and preliminary efficacy of a CRPM solution in patients with HF at NorthShore University HealthSystem.
This study is a feasibility study and uses a wearable biosensor to continuously remotely monitor patients with HF for 30 days after discharge. Eligible patients admitted with an HF exacerbation at NorthShore University HealthSystem are being recruited, and the wearable biosensor is placed before discharge. The biosensor collects physiological ambulatory data, which are analyzed for signs of patient deterioration. Participants are also completing a daily survey through a dedicated study smartphone. If prespecified criteria from the physiological data and survey results are met, a notification is triggered, and a predetermined electronic health record-based pathway of telephonic management is completed. In phase 1, which has already been completed, 5 patients were enrolled and monitored for 30 days after discharge. The results of phase 1 were analyzed, and modifications to the program were made to optimize it. After analysis of the phase 1 results, 15 patients are being enrolled for phase 2, which is a calibration and testing period to enable further adjustments to be made. After phase 2, we will enroll 45 patients for phase 3. The combined results of phases 1, 2, and 3 will be analyzed to determine the feasibility of a CRPM program in patients with HF. Semistructured interviews are being conducted with key stakeholders, including patients, and these results will be analyzed using the affective adaptation of the technology acceptance model.
During phase 1, of the 5 patients, 2 (40%) were readmitted during the study period. The study completion rate for phase 1 was 80% (4/5), and the study attrition rate was 20% (1/5). There were 57 protocol deviations out of 150 patient days in phase 1 of the study. The results of phase 1 were analyzed, and the study protocol was adjusted to optimize it for phases 2 and 3. Phase 2 and phase 3 results will be available by the end of 2022.
A CRPM program may offer a low-risk solution to improve care of patients with HF after hospital discharge and may help to decrease readmission of patients with HF to the hospital. This protocol may also lay the groundwork for the use of CRPM solutions in other groups of patients considered to be at high risk.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/36741.
心力衰竭(HF)是一种常见的慢性疾病,与死亡率和发病率的增加相关。HF是美国住院和再入院的主要原因。持续远程患者监测(CRPM)是预防HF再入院的一个潜在有前景的领域。
本研究的主要目的是确定CRPM解决方案在北岸大学健康系统的HF患者中的可行性和初步疗效。
本研究是一项可行性研究,使用可穿戴生物传感器在出院后对HF患者进行30天的持续远程监测。正在招募北岸大学健康系统因HF加重而入院的符合条件的患者,并在出院前放置可穿戴生物传感器。该生物传感器收集动态生理数据,对其进行分析以寻找患者病情恶化的迹象。参与者还通过专门的研究智能手机完成每日调查。如果生理数据和调查结果符合预先设定的标准,将触发通知,并完成基于预定电子健康记录的电话管理路径。在已经完成的第1阶段,招募了5名患者并在出院后对其进行了30天的监测。对第1阶段的结果进行了分析,并对方案进行了修改以优化它。在分析第1阶段的结果后,正在招募15名患者进入第2阶段,这是一个校准和测试期,以便能够进行进一步调整。第2阶段之后,我们将招募45名患者进入第3阶段。将对第1、2和3阶段的综合结果进行分析,以确定CRPM方案在HF患者中的可行性。正在与包括患者在内的关键利益相关者进行半结构化访谈,并将使用技术接受模型的情感适应对这些结果进行分析。
在第1阶段,5名患者中有2名(40%)在研究期间再次入院。第1阶段的研究完成率为80%(4/5),研究损耗率为20%(1/5)。在研究的第1阶段,150个患者日中有57次方案偏差。对第1阶段的结果进行了分析,并对研究方案进行了调整,以便在第2和第3阶段对其进行优化。第2阶段和第3阶段的结果将于2022年底公布。
CRPM方案可能提供一种低风险的解决方案,以改善HF患者出院后的护理,并可能有助于减少HF患者再次入院。该方案还可能为在其他被认为高风险的患者群体中使用CRPM解决方案奠定基础。
国际注册报告识别码(IRRID):DERR1-10.2196/36741。